Intranasal oxytocin as a treatment for anxiety and autism: From subclinical to clinical applications.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Intranasal oxytocin as a treatment for anxiety and autism: From subclinical to clinical applications.
- Published In:
- Peptides, 176, 171211 (2024)
- Authors:
- Yin, Hailian, Jiang, Meiyun, Han, Tao, Xu, Xiaolei
- Database ID:
- RPEP-09604
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-09604APA
Yin, Hailian; Jiang, Meiyun; Han, Tao; Xu, Xiaolei. (2024). Intranasal oxytocin as a treatment for anxiety and autism: From subclinical to clinical applications.. Peptides, 176, 171211. https://doi.org/10.1016/j.peptides.2024.171211
MLA
Yin, Hailian, et al. "Intranasal oxytocin as a treatment for anxiety and autism: From subclinical to clinical applications.." Peptides, 2024. https://doi.org/10.1016/j.peptides.2024.171211
RethinkPeptides
RethinkPeptides Research Database. "Intranasal oxytocin as a treatment for anxiety and autism: F..." RPEP-09604. Retrieved from https://rethinkpeptides.com/research/yin-2024-intranasal-oxytocin-as-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.